NATR vs. VSTM, VERU, ADCT, HROW, ESPR, RVNC, AMRN, LXRX, MREO, and HRTX
Should you be buying Nature's Sunshine Products stock or one of its competitors? The main competitors of Nature's Sunshine Products include Verastem (VSTM), Veru (VERU), ADC Therapeutics (ADCT), Harrow Health (HROW), Esperion Therapeutics (ESPR), Revance Therapeutics (RVNC), Amarin (AMRN), Lexicon Pharmaceuticals (LXRX), Mereo BioPharma Group (MREO), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical preparations" industry.
Nature's Sunshine Products (NASDAQ:NATR) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.
Verastem received 433 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 65.20% of users gave Verastem an outperform vote while only 62.89% of users gave Nature's Sunshine Products an outperform vote.
In the previous week, Nature's Sunshine Products had 9 more articles in the media than Verastem. MarketBeat recorded 17 mentions for Nature's Sunshine Products and 8 mentions for Verastem. Nature's Sunshine Products' average media sentiment score of 1.17 beat Verastem's score of 0.16 indicating that Nature's Sunshine Products is being referred to more favorably in the media.
79.4% of Nature's Sunshine Products shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 4.7% of Nature's Sunshine Products shares are held by insiders. Comparatively, 2.2% of Verastem shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Nature's Sunshine Products has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Nature's Sunshine Products presently has a consensus target price of $24.00, indicating a potential upside of 45.72%. Verastem has a consensus target price of $28.79, indicating a potential upside of 142.92%. Given Verastem's higher probable upside, analysts clearly believe Verastem is more favorable than Nature's Sunshine Products.
Nature's Sunshine Products has a net margin of 3.69% compared to Verastem's net margin of 0.00%. Nature's Sunshine Products' return on equity of 10.59% beat Verastem's return on equity.
Nature's Sunshine Products has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.
Summary
Nature's Sunshine Products beats Verastem on 11 of the 17 factors compared between the two stocks.
Get Nature's Sunshine Products News Delivered to You Automatically
Sign up to receive the latest news and ratings for NATR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NATR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nature's Sunshine Products Competitors List
Related Companies and Tools
